{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T09:15:33Z","timestamp":1753521333842,"version":"3.40.5"},"reference-count":20,"publisher":"Wiley","issue":"16","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Brain metastases (BM) are common in patients with epidermal growth factor receptor (EGFR)\u2010mutant non\u2010small cell lung cancer (NSCLC) and confer poor prognoses. Zorifertinib (AZD3759), an EGFR\u2010tyrosine kinase inhibitor (TKI) with high blood\u2010brain barrier penetration, has previously demonstrated promising systemic and intracranial antitumor activity in phase 1\u20133 studies. This is the first report of a patient with <jats:italic>EGFR<\/jats:italic>\u2010mutant (exon 21 L858R) NSCLC and symptomatic untreated multiple BM who achieved a long overall survival (OS) of more than 65 months after sequential treatment with zorifertinib and a third\u2010generation EGFR\u2010TKI. This new treatment paradigm offers a new treatment option and deserves further clinical exploration to prolong OS of patients with <jats:italic>EGFR<\/jats:italic>\u2010mutant NSCLC and untreated multiple BM.<\/jats:p>","DOI":"10.1111\/1759-7714.15317","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T09:29:19Z","timestamp":1714123759000},"page":"1325-1329","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long\u2010term survival of a patient with epidermal growth factor receptor (<scp>EGFR)<\/scp>\u2010mutant non\u2010small cell lung cancer (<scp>NSCLC)<\/scp> and untreated multiple brain metastases treated with zorifertinib: A case report"],"prefix":"10.1111","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2615-9197","authenticated-orcid":false,"given":"Kang","family":"Li","sequence":"first","affiliation":[{"name":"Department of Thoracic Medical Oncology Hunan Cancer Hospital\/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University  Changsha China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1007-0486","authenticated-orcid":false,"given":"Bolin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medical Oncology Hunan Cancer Hospital\/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University  Changsha China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8306-6395","authenticated-orcid":false,"given":"Jingyi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medical Oncology Hunan Cancer Hospital\/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University  Changsha China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7078-7767","authenticated-orcid":false,"given":"Lin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medical Oncology Hunan Cancer Hospital\/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University  Changsha China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,4,26]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02314"},{"key":"e_1_2_8_3_1","unstructured":"National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae) non\u2010small cell lung cancer version 2.2024.2024https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf"},{"issue":"6","key":"e_1_2_8_4_1","first-page":"457","article-title":"Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2022 edition)","volume":"44","author":"Oncology Society of Chinese Medical Association, Chinese Medical Association Publishing House","year":"2022","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"3","key":"e_1_2_8_5_1","first-page":"269","article-title":"Clinical practice guideline for brain metastases of lung cancer in China (2021 version)","volume":"43","author":"Chinese Association for Clinical Oncologists, Medical Oncology Branch of Chinese International Exchange and Promotion Association for Medical and Healthcare","year":"2021","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.02.003"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-021-01955-7"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.05.125"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33904"},{"issue":"02","key":"e_1_2_8_10_1","first-page":"110","article-title":"Prognostic analysis of osimertinib in the treatment of brain metastases from EGFR\u2010mutant non\u2010small\u2010cell lung cancer","volume":"41","author":"Zhang BY","year":"2021","journal-title":"Tumor"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30378-8"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag0976"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102238"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.9001"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913662"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00794-6"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01521"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030841"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30689-7"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-22-1671"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-21-451"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.15317","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T01:20:47Z","timestamp":1717464047000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.15317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,26]]},"references-count":20,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1111\/1759-7714.15317"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.15317","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"type":"print","value":"1759-7706"},{"type":"electronic","value":"1759-7714"}],"subject":[],"published":{"date-parts":[[2024,4,26]]},"assertion":[{"value":"2024-02-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}